Clinical operations

What Trials Can Miss When They Measure Brain Injury Recovery Once

A perfect-pitch case and the TRACK-TBI cohort show why brain injury studies need meaningful outcomes, well-timed assessments, and accessible follow-up.

By Lampgen Clinical Research

Headphones and an open notebook beside an abstract teal waveform. The Lampgen Clinical Insights graphic reads “Measuring recovery after brain injury.”
Editorial illustration of headphones, a notebook, and an abstract sound wave.
2 weeks12 months
First and final assessment windows in the TRACK-TBI analysis of moderate or severe traumatic brain injury [5]

What the source reported

In a traumatic brain injury (TBI) study, the timing of follow-up and the choice of outcome measure determine which parts of recovery the trial can see. A music teacher’s unusual experience shows how different abilities can change during recovery. A larger multicenter study shows why the assessment window matters for everyday function. [1, 5]

The case behind the perfect pitch story

After a motorcycle crash, musician and teacher Edward Freytag could identify a note without hearing a reference tone, a skill called absolute pitch. He also described seeing musical notation in his mind while listening, a form of synesthesia. Vanderbilt clinicians documented the case in Neurocase in 2023. They described roughly four months of unusual sensory and creative changes overall. Difficulties with attention and memory also surfaced early in recovery. The New York Times Magazine revisited the case in November 2026. [1–4]

Freytag’s experience raises a question about how auditory perception can change after injury. Establishing how often this happens or what caused it would require a larger group with systematic measurements over time. For trial teams, the observation illustrates how a measure designed to capture overall disability could miss an important change in one ability.

What TRACK-TBI found over the first year

TRACK-TBI investigators analyzed a prospective observational cohort of 484 participants with moderate or severe TBI recruited at 18 U.S. level 1 trauma centers. They used the Glasgow Outcome Scale–Extended and the Disability Rating Scale to assess overall function at two weeks and at three, six and 12 months. Most of the measured improvement occurred early, with additional gains between months six and 12. [5]

At 12 months, 142 of 271 participants with available outcomes in the severe TBI group and 54 of 72 in the moderate group could spend at least eight hours at home independently. Those denominators are smaller than the original groups of 362 and 122 participants, respectively. [5]

What this means for trial teams

Choose outcomes with patients and caregivers. Ask what people want to get back to, such as keeping track of a conversation, managing a daily routine or returning to work. A global functional measure can capture broad independence. If the intervention is expected to affect a specific domain like attention or fatigue, consider a fit-for-purpose measure for that domain and define in advance how the study will use it. The FDA’s final guidance addresses measure selection for a defined context of use, and NINDS provides common data elements for TBI research. [6, 7]

Match follow-up windows to the expected course of change. Choose early and later time points that fit the study question. At site startup, calibrate raters with the same practice cases and agree on who can complete an assessment when a participant is unable to respond. Where caregiver or proxy input is allowed, record the respondent so the analysis can distinguish their observations from the participant’s report. [5–7]

Find out why assessments go missing. Review missing visits and assessments by site, window and reason. A person who can’t travel after a brain injury and a site that loses rater coverage leave the same blank field for different reasons. Before enrollment, plan for accessible scheduling, travel support and protocol-approved remote collection where the measure is suitable for that mode. If gaps recur, assign an owner and check whether completion improves in the next window. [8]

Oncology trials face a similar problem when collecting symptoms after treatment ends. The analysis can become less representative when the people with the most difficulty returning are also the people whose function or symptoms changed most. Decide at startup who owns continued follow-up and how the team will identify a pattern early enough to act. [9]

Sources

  1. Abou-Khalil and Acosta, Neurocase (2023) • Original case report on acquired synesthesia and creativity
  2. Vanderbilt Health (2023) • Clinical account and testing
  3. Sadie Dingfelder, The New York Times Magazine (November 2026) • Feature on Edward Freytag
  4. Nature Briefing (November 2026) • Coverage of Freytag’s case
  5. McCrea et al., JAMA Neurology (2021) • First-year functional outcomes in TRACK-TBI
  6. FDA (October 2025) • Final guidance on fit-for-purpose clinical outcome assessments
  7. NINDS • Common data elements for traumatic brain injury
  8. Related Lampgen insight • Clinical trial participation burden and patient access
  9. Related Lampgen insight • Patient-reported outcomes in oncology trials

AVAILABLE FOR NEW PARTNERSHIPS

What does your clinical team need next?